<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218657</url>
  </required_header>
  <id_info>
    <org_study_id>AA-LSA/SA</org_study_id>
    <nct_id>NCT03218657</nct_id>
  </id_info>
  <brief_title>Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole</brief_title>
  <official_title>A Prospective, Randomized, Controlled Clinical Study of Non Transfusion Dependent Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Hydrochloride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengyun Lin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Provincial Hospital of TCM</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical symptoms of non transfusion dependent non severe aplastic anemia (NSAA) are
      often lighter than that of severe aplastic anemia. Clinical observation is often used and the
      treatment should be given according to the follow-up results of peripheral blood routine and
      the survival condition of the patients. In recent years, a number of studies at home or
      abroad have tended to intervene earlier. The risk of observation and waiting for disease
      progression is higher. Early immunosuppression should be considered. For the treatment of non
      transfusion dependent non severe aplastic anemia, the commonly used treatment regimen is
      androgen combined with CSA. But the investigators find that Levamisole hydrochloride (LMS) as
      a commonly used immunomodulatory drugs may be helpful to improving immune disorder symptoms
      in NSAA patients. Therefore,the investigators are conducting a prospective, randomized
      controlled study to compare the rate, side effects and long-term survival in non transfusion
      dependent patients with NSAA between the androgen+CSA group and the androgen+CSA+LMS group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Routine blood test</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>hemoglobin；white blood cell；Platelet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone marrow</measure>
    <time_frame>1 year</time_frame>
    <description>The proliferation of cells in bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical test</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Alanine aminotransferase；Aspartate aminotransferase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients treated with levamisole hydrochloride 150mg qod +androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>the patients treated without levamisole hydrochloride，but androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levamisole hydrochloride</intervention_name>
    <description>levamisole hydrochloride take orally 150mg qod</description>
    <arm_group_label>experimental group</arm_group_label>
    <other_name>levamisole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androgens</intervention_name>
    <description>Androgens take orally 80mg qd</description>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporins</intervention_name>
    <description>Cyclosporines take orally 3-5mg/kg*d qd</description>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All the patients meet a NSAA diagnostic criteria, and agree the immunosuppressive
             therapy. Diagnoses reference to The diagnostic and therapeutic criteria for
             hematologic diseases（Zhang Zhinan 2007）, and The diagnosis and treatment of aplastic
             anemia（2016 UK guidelines）

          2. 18-70years old, male or female

          3. Liver and kidney function: the blood bilirubin is less than or equal to 2mg/dL (35
             mol/L), AST/ALT in the upper limit of the normal value below 2 times, blood inosine is
             less than or equal to 177 umol/L.

          4. Heart function is normal: EF&gt;50%.

          5. No serious lung infection.

          6. All cases had no history of cancer and chemotherapy history, immunology therapy. The
             control group without hematologic diseases, lupus or other immune disfunctions,
             allergic disease, Fanconi anemia.

          7. Consent signed by patients or their families.

        Exclusion Criteria:

          1. Congenital hematopoietic failure, Fanconi anemia, or combined with bone marrow
             hyperplasia, leukemia, multiple myeloma, giant cell anemia, paroxysmal nocturnal
             hemoglobin or other blood diseases.

          2. The HBV DNA copy number is greater than 1000/ml or the serum hepatitis B virus is not
             clear.

          3. Serum bilirubin &gt; 2mg/dL (35 umol/L); ALT or AST &gt; 2 times the normal value of the
             upper limit; alkaline phosphatase &gt; 3 times the upper limit of the normal value; serum
             creatinine &gt; 177 mol/L.

          4. HIV positive.

          5. Other serious diseases that may limit the patient to participate in the study (e.g.,
             the progressive infection, incontrollable diabetes, severe cardiac insufficiency or
             angina pectoris, etc.)

          6. Conditions are not suitable for immunosuppressive therapy.

          7. Pregnant or lactating women.

          8. Can not understand or follow the research program.

          9. Patients under 16 years of age.

         10. Patients with a history of cancer, chemotherapy, or radiation therapy, immune system
             diseases or allergic diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin S Yun, master</last_name>
    <phone>13588887285</phone>
    <email>lsyww2003@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>shen y Ying, master</last_name>
    <phone>18368023551</phone>
    <email>413808426@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Province Traditional Chinese Medical Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin s Yun, master</last_name>
      <phone>13588887285</phone>
      <email>lsyww2003@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Provincial Hospital of TCM</investigator_affiliation>
    <investigator_full_name>Shengyun Lin</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <keyword>Aplastic Anemia</keyword>
  <keyword>levamisole hydrochloride</keyword>
  <keyword>clinical study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Levamisole</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

